Literature DB >> 31160773

Achaogen bankruptcy highlights antibacterial development woes.

Asher Mullard.   

Abstract

Keywords:  Antibiotics; Drug discovery

Year:  2019        PMID： 31160773     DOI： 10.1038/d41573-019-00085-w

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  5 in total

1.  A novel pre-clinical antibacterial pipeline database.

Authors:  Sarah Paulin; Richard A Alm; Peter Beyer
Journal:  PLoS One       Date:  2020-07-28       Impact factor: 3.240

2.  Narrow-Spectrum Antibacterial Agents-Benefits and Challenges.

Authors:  Richard A Alm; Sushmita D Lahiri
Journal:  Antibiotics (Basel)       Date:  2020-07-17

3.  The Production of Antibiotics Must Be Reoriented: Repositioning Old Narrow-Spectrum Antibiotics, Developing New Microbiome-Sparing Antibiotics.

Authors:  Sylvain Diamantis; Nicolas Retur; Benjamin Bertrand; Florence Lieutier-Colas; Philippe Carenco; Véronique Mondain
Journal:  Antibiotics (Basel)       Date:  2022-07-08

Review 4.  Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions.

Authors:  Kathleen Tompkins; David van Duin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-06-24       Impact factor: 5.103

5.  There is no market for new antibiotics: this allows an open approach to research and development.

Authors:  Dana M Klug; Fahima I M Idiris; Mark A T Blaskovich; Frank von Delft; Christopher G Dowson; Claas Kirchhelle; Adam P Roberts; Andrew C Singer; Matthew H Todd
Journal:  Wellcome Open Res       Date:  2021-06-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.